- XIENCE Skypoint has the broadest size range and is the only one indicated for vessels up to 5.25 mm
- Device is designed for complex percutaneous coronary interventions (PCI), a minimally invasive procedure to open blocked heart arteries, including long lesions, large vessels and the left main coronary artery
NEW DELHI | 10th MARCH 2026 — Abbott, the global healthcare company, today announced the launch of XIENCE Skypoint in India. This is Abbott’s most advanced generation stent within the globally trusted XIENCE™ family of everolimus (drug)-eluting coronary stents.The stent is designed to be more flexible, easier to guide through the heart’s arteries, including large vessels, and better suited for treating complex heart blockages.[i]
Tushar Sharma, general manager for Abbott’s vascular business in India and South Asia said, “The launch of XIENCE Skypoint in India represents an advancement for doctors treating cardiovascular disease, which remains a leading cause of mortality in India. Many patients today develop severe blockages earlier in life due to rising hypertension, diabetes, cholesterol, and lifestyle risks. This makes it essential to support doctors with stents that can safely reach difficult areas and treat a wide range of blockages. XIENCE Skypoint brings improvements with precision and strengthens our commitment to providing advanced heart treatments across the country.”
Broader size range for Indian patients
Abbott hasintroduced newer generations of XIENCE, with the goal of providing physicians with access to the latest DES technology. With this launch, XIENCE Skypoint brings the broadest size matrix ever offered by the XIENCE family, supporting the treatment of long lesions while helping reduce the number of stents required per procedure.The platform also introduces 4.5 mm and 5.0 mm diameters, making it the only DES indicated for vessels up to 5.25 mm. This is especially important because real‑world patients at times have bigger or more varied artery sizes that need the right fit.
A single-stent solution for long lesions (blockages)
Many patients require treatment for long blockages. Traditionally, cardiologists used two or more overlapping stents, increasing procedure complexity. With XIENCE Skypoint, doctors have the option of using a 48 mm single‑stent, allowing them to treat longer lesions with one stent instead of multiple ones. This can reduce procedure time, radiation exposure, and contrast dye usage for patients.[ii]
Smarter design for smoother navigation
XIENCE Skypoint is designed to move more easily through the heart’s arteries. It uses a slim and smooth delivery system that helps doctors guide the stent through tight or winding passages with better control. These improvements make it easier to reach tough blockages, supporting reliable performance even in complicated cases.
Treating one of the heart’s most critical arteries
XIENCE Skypoint includes a left‑main indication, helping doctors with more options when treating one of the most critical segments of the coronary artery. The left main coronary artery is one of most crucial blood vessels in the heart. It supplies blood to a very large portion of the heart. A blockage here is extremelyhigh risk because it affects two other major branches. Treating left main disease has traditionally required coronary artery bypass grafting (CABG) due to its complexity. But advances such as XIENCE Skypoint now allow interventions with stents to be a viable alternative in selected patients.
XIENCE Skypoint is built on the established XIENCE legacy, one of the world’s most studied DES platforms. It is supported by years of clinical evidence, with over 120 clinical trials3 and 10 years of clinical data[iii]. Globally, there have been 20 million+ implants using XIENCE stents. The stent is also backed by Abbott’s proprietary fluoropolymer coating, and a proven cobalt‑chromium structure, continuing a long‑standing record of safety and durable outcomes.
Ultimately, the goal is to give doctors more options and patients greater confidence—supporting long‑term heart health and helping people continue to live healthier, fuller lives.
